CLEVELAND BIOLABS INC

CLEVELAND BIOLABS INC insiders are currently net sellers of CBLI stock, showing bearish sentiment over the past 90 days. Total sales of $1.2M outpace purchases of $257.6K, creating a net outflow of $899.8K.

CLEVELAND BIOLABS INC has 19 active insiders who have filed SEC Form 4 transactions in the past 90 days. Michael Fonstein (Executive) leads with 64 transactions totaling $484.9K. Securities Corp Sunrise (Executive) follows with 4 transactions worth $299.4K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. CLEVELAND BIOLABS INC's current score of 18/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Jul 27, 2021, when Aronstam Peter (Executive) acquired 141,370 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, CBLI insider trading sentiment is currently bearish with an Alignment Score of 18/100. The negative net flow of $899.8K shows more selling than buying. However, 0% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like CLEVELAND BIOLABS INC. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At CBLI, we track all Form 4 filings—currently showing 272 transactions from 19 insiders over 90 days.

A 10b5-1 plan allows CLEVELAND BIOLABS INC executives to pre-schedule stock sales when they don't possess material non-public information. At CBLI, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at CBLI appears discretionary, making insider signals more meaningful.

You can monitor CLEVELAND BIOLABS INC (CBLI) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 19 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. CLEVELAND BIOLABS INC's current score of 18/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $257.6K in purchases versus $1.2M in sales over 90 days, resulting in a net flow of -$899.8K.

SEC Form 4 filings are mandatory reports that CLEVELAND BIOLABS INC insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At CBLI, the most common type is "A" with 22 occurrences. The most recent Form 4 was filed on Jul 27, 2021 by Aronstam Peter.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At CLEVELAND BIOLABS INC, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at CBLI represents discretionary decisions with more informational value.